MH & Associates Securities Management Corp ADV Buys New Stake in Viking Therapeutics, Inc.

The firm bought 43,634 shares of the biotechnology company's stock, valued at approximately $1.5 million.

Apr. 9, 2026 at 11:06am

Got story updates? Submit your updates here. ›

An extreme close-up of a network of interlocking metal gears and machinery, representing the behind-the-scenes financial infrastructure supporting the biotechnology sector.This institutional investment in a promising biotech company reflects the complex financial mechanisms powering the healthcare industry.San Diego Today

MH & Associates Securities Management Corp ADV, an investment management firm, has bought a new stake in Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. The firm purchased 43,634 shares of Viking Therapeutics' stock in the fourth quarter, valued at around $1.5 million.

Why it matters

This investment by MH & Associates Securities Management Corp ADV in Viking Therapeutics reflects the growing interest and confidence in the company's pipeline of drug candidates, particularly its lead programs VK2809 for NASH and dyslipidemia, and VK5211 for muscle wasting conditions. As Viking Therapeutics continues to advance its clinical trials, this new institutional investment could provide additional financial resources and validation for the company's research and development efforts.

The details

According to the filing with the Securities and Exchange Commission, MH & Associates Securities Management Corp ADV bought 43,634 shares of Viking Therapeutics' stock in the fourth quarter of 2025. This new stake in the biotechnology company is valued at approximately $1.5 million. Several other institutional investors also recently bought and sold shares of Viking Therapeutics, with some increasing their positions in the company.

  • MH & Associates Securities Management Corp ADV bought the new stake in Viking Therapeutics in the 4th quarter of 2025.
  • The filing with the SEC detailing this new investment was made on April 9, 2026.

The players

MH & Associates Securities Management Corp ADV

An investment management firm that has bought a new stake in Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders.

Got photos? Submit your photos here. ›

The takeaway

This new investment by MH & Associates Securities Management Corp ADV in Viking Therapeutics highlights the growing institutional interest and confidence in the biotechnology company's pipeline of drug candidates targeting metabolic and endocrine disorders. As Viking Therapeutics continues to advance its clinical trials, this additional financial backing could provide valuable resources to support the company's ongoing research and development efforts.